These results should be tested further in prospective patient cohorts, to investigate the possibility that including IL7R signaling inhibitors in treatment regimens could restore or enhance steroid sensitivity in patients with ALL, thereby improving clinical outcomes. Here, IL7R is linked to acute lymphoblastic leukemia.